Antibody which specifically binds to endothelial-monocyte activating polypeptide II
US5641867A · kind A · utility
33Cited by
7References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1993 |
| Grant date | Jun 24, 1997 |
| Priority date | — |
| Expiry date | Sep 29, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a purified endothelial monocyte activating polypeptide (EMAP II). It further provides a method of obtaining purified endothelial monocyte activating polypeptide (EMAP II), a method of making antibodies to it and a method of detecting it. This invention also provides an effector cell activating protein which contains an amino acid sequence homologous to RIGRIVT and a method of detecting same. This invention also provides a method of treating a tumor in a subject by administering an effective dose of endothelial monocyte activating polypeptide (EMAP II).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.